Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

J.-M. Molina; J. Andrade-Villanueva; I.M. Hoepelman; Study Team Castle

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Translated title of the contribution: Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

J.-M. Molina
, J. Andrade-Villanueva
, I.M. Hoepelman
, Study Team Castle

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Original language	Undefined/Unknown
Pages (from-to)	646-655
Number of pages	10
Journal	The Lancet
Volume	372
Issue number	9639
Publication status	Published - 2008

Cite this

@article{b61920874f104c55889e23fbd2e01ca7,

title = "Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.",

author = "J.-M. Molina and J. Andrade-Villanueva and I.M. Hoepelman and Castle, \{Study Team\}",

year = "2008",

language = "Undefined/Unknown",

volume = "372",

pages = "646--655",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9639",

}

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. / Molina, J.-M.; Andrade-Villanueva, J.; Hoepelman, I.M. et al.
In: The Lancet, Vol. 372, No. 9639, 2008, p. 646-655.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

AU - Molina, J.-M.

AU - Andrade-Villanueva, J.

AU - Hoepelman, I.M.

AU - Castle, Study Team

PY - 2008

Y1 - 2008

M3 - Article

SN - 0140-6736

VL - 372

SP - 646

EP - 655

JO - The Lancet

JF - The Lancet

IS - 9639

ER -